Step into Pharma’s Age of Uncertainty, where all is in flux. From the FDA's shifting mood and the ripple effects of the IRA to commercial upheavals, dealmaking uncertainties and emerging R&D mechanisms, we've identified the pivotal forces that are redefining the pharma and biotech landscape out to 2028. 

Download Evaluate's World Preview 2023: Pharma's Age of Uncertainty report here!

.

HIGHLIGHTS INCLUDE:

Prescription drug sales to 2028: A steady climb or a plateau in sight?
The blockbuster drugs facing patent expiry pressures
Biologics or conventional drugs: Who's topping the sales chart?
The players and products set to dominate the global market
A return to growth for R&D spend after the post-pandemic pullback?
Any many more